Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07136805
Active, not recruiting Phase 3

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

NCT07136805 · tracked via the Priya Life Science China tracker
Sponsor
VivaVision Biotech, Inc
Phase
Phase 3
Started
2025-11-25
Last updated
2026-08-24

Condition(s) studied

Non-infectious Anterior Uveitis

Investigational drug(s) / intervention(s)

VVN461 Ophthalmic Solution 1.0%1.0% prednisolone acetate →

VVN461 Ophthalmic Solution 1.0%: 1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

1.0% prednisolone acetate: 1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days

Study summary

This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive); * At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included); * At screening, the ACC grade of the affected eye is 2+ or 3+ \[SUN criteria\]; * At screening, the ACF grade of the affected eye is ≥1 \[SUN criteria\]; Exclusion Criteria: * At screening, the affected eye has an ACC grade of 4+ or hypopyon * Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening

Primary outcome measure(s)

  • Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14 — Day 14

Trial sites (2)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality
Peking University First Hospital Beijing China

More VivaVision Biotech, Inc trials in China

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease Recruiting
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07136805 on ClinicalTrials.gov ↗ ← All trials in China